Intermedin promotes hepatocellular carcinoma cell proliferation through the classical Wnt signaling pathway

  • Authors:
    • Hai Shang
    • Zhi Qiang Hao
    • Xi Bo Fu
    • Xiang Dong Hua
    • Zuo Hong Ma
    • Fu Lu Ai
    • Zhao Qiang Feng
    • Kun Wang
    • Wen Xin Li
    • Bo Li
  • View Affiliations

  • Published online on: February 13, 2018     https://doi.org/10.3892/ol.2018.8033
  • Pages: 5966-5970
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The proliferative activity of hepatic carcinoma cells is directly associated with tumorigenesis, tumor development, metastasis and invasion. A variety of cytokines and peptides serve important roles in the development of hepatic carcinoma. The aim of the present study was to examine the effect of intermedin (IMD) on hepatic carcinoma cell proliferation and its mechanism of action. HepG2 hepatic carcinoma cell lines were treated with human recombinant IMD1‑53 and its receptor antagonist IMD17‑47. Cell proliferation was detected using a Cell Counting kit‑8. The activation of the classical Wnt signaling pathway was demonstrated by the ratio of TOPflash:FOPflash luciferase activity. The expression of c‑Myc and cyclin D1 downstream of the Wnt signaling pathway were detected using reverse transcription‑quantitative polymerase chain reaction analysis. It was demonstrated that IMD may promote the proliferation of HepG2 cells in a time‑dependent manner, and that the IMD receptor antagonist IMD17‑47 could eliminate this promotion. IMD may activate classical Wnt signaling pathway transcriptional activity and the mRNA levels of certain downstream target genes. Furthermore, blocking of the Wnt signaling pathway may inhibit IMD‑induced HepG2 cell proliferation to a certain extent. IMD may promote hepatic carcinoma cell proliferation by binding with receptor antagonist IMD17‑47 and activating the Wnt signaling cascade, thus providing a novel avenue for the treatment of hepatic carcinoma.
View Figures
View References

Related Articles

Journal Cover

April-2018
Volume 15 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Shang H, Hao ZQ, Fu XB, Hua XD, Ma ZH, Ai FL, Feng ZQ, Wang K, Li WX, Li B, Li B, et al: Intermedin promotes hepatocellular carcinoma cell proliferation through the classical Wnt signaling pathway. Oncol Lett 15: 5966-5970, 2018
APA
Shang, H., Hao, Z.Q., Fu, X.B., Hua, X.D., Ma, Z.H., Ai, F.L. ... Li, B. (2018). Intermedin promotes hepatocellular carcinoma cell proliferation through the classical Wnt signaling pathway. Oncology Letters, 15, 5966-5970. https://doi.org/10.3892/ol.2018.8033
MLA
Shang, H., Hao, Z. Q., Fu, X. B., Hua, X. D., Ma, Z. H., Ai, F. L., Feng, Z. Q., Wang, K., Li, W. X., Li, B."Intermedin promotes hepatocellular carcinoma cell proliferation through the classical Wnt signaling pathway". Oncology Letters 15.4 (2018): 5966-5970.
Chicago
Shang, H., Hao, Z. Q., Fu, X. B., Hua, X. D., Ma, Z. H., Ai, F. L., Feng, Z. Q., Wang, K., Li, W. X., Li, B."Intermedin promotes hepatocellular carcinoma cell proliferation through the classical Wnt signaling pathway". Oncology Letters 15, no. 4 (2018): 5966-5970. https://doi.org/10.3892/ol.2018.8033